Clinical-stage biotechnology company Innate Pharma SA (Euronext Paris:IPH) (Nasdaq:IPHA) on Friday announced long-term data from its Phase 2 TELLOMAK trial, confirming durable responses to lacutamab in patients with Sézary syndrome (SS) and mycosis fungoides (MF).

The results will be shared at the 2025 American Society of Clinical Oncology Annual Meeting.

In heavily pretreated SS patients, lacutamab achieved a global overall response rate (ORR) of 42.9% with a median response duration of 25.6 months. For MF, the ORR was 19.6%, with durable responses seen regardless of KIR3DL2 expression levels at baseline.

These data underscore lacutamab's clinical relevance in a population with limited treatment options and multiple prior systemic therapies. The antibody also demonstrated a favourable safety profile, supporting its continued development.

Lacutamab recently received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of SS. Innate Pharma is preparing a Phase 3 trial to advance regulatory discussions and expand access.

Further investigation of lacutamab in combination with other anti-lymphoma agents, particularly in peripheral T-cell lymphomas, is being considered.